TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06232304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH
Description: TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
Study: NCT05513534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A standard yoga program will be provided using Hatha poses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed Resistance Training
Description: Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
Study: NCT06176235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
Study: NCT06278714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances
Study: NCT06041607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared meditation
Description: Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation with patients oly
Description: Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)
Study: NCT04887129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 RT-PCR test
Description: Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Education Campaign
Description: Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
Study: NCT06256796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fresh frozen plasma
Description: repeated doses of fresh plasma over 3 days in organophosphate poisoned patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fresh frozen plasma
Description: repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
Study: NCT04932486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation of the upper airway muscles
Study: NCT04944004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogniPlus
Description: The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training As Usual (TAU)
Description: Training As Usual (TAU)
Study: NCT05812911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen
Description: Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted.
Study: NCT05498714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+lactulose
Description: On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSP＋lactulose
Description: On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
Study: NCT06170294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR-MAGE-A4 T-Cells
Description: * Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells
Study: NCT00809952

Intervention type: PROCEDURE
Intervention: recombinant FSH
Study: NCT04943653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)
Study: NCT05738304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery with external ureteral catheter
Description: The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery with double J internal ureteral stent
Description: The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
Study: NCT04587427

Intervention type: DRUG
Intervention: Radium 223 dichloride (Xofigo, BAY88-8223)
Description: Prescribed by physicians.
Study: NCT04767919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Percutaneous Nephrolithotomy (sPCNL)
Description: Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Percutaneous Nephrolithotomy (MIP)
Description: Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
Study: NCT05611320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Awareness campaign - communications campaign
Description: How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online shopping
Description: Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
Study: NCT05465577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC Links
Description: The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC Links
Description: The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
Study: NCT06035757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bridion 200 MG in 2 ML Injection
Description: Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide 5 MG/ML
Description: Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
Study: NCT06246461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
Study: NCT04876469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion
Description: Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion
Description: Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
Study: NCT05679258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX15
Description: A single dose (8 mg/kg) of HLX15 via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced DARZALEX®
Description: A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-sourced DARZALEX®
Description: A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced DARZALEX®
Description: A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
Study: NCT04355039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 50 mg bis in die (BID)
Description: Dose level 0: 50 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 65 mg BID
Description: Dose level 1: 65 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914 80 mg BID
Description: Dose level 2: 80 mg BID
Study: NCT06315816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality glasses used during tooth extraction and extirpation treatment
Description: The effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in 7-10 years old children
Study: NCT05324852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular loxapine
Description: Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
Study: NCT05196295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
Study: NCT04367818

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-anal local anaesthetic infiltration
Description: postoperative pain relieve, among pediatrics patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal anaesthesia
Description: Regional anaesthesia for postoperative pain relieve, among pediatrics patient
Study: NCT05711212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar solubilized Xanthohumol
Description: single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration of 4 soft gelatine capsules containing only micelles
Study: NCT04805398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: 300 mg every two weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg every two weeks
Study: NCT04961957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Waterproof padding
Description: Apply waterproof padding to allow for normal bathing and water activities

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-waterproof padding
Description: Apply standard padding that does not allow for normal bathing and water activities
Study: NCT05579613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality device
Description: The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive virtual reality device
Description: The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
Study: NCT05322395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ESC 0/1 hour troponin pathway
Description: randomisation to 0/1 versus 0/3 hour pathway

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ESC 0/1 hour troponin pathway
Description: randomisation to 0/1 versus 0/3 hour pathway
Study: NCT06440681

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Providing nutritional counselling
Description: Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Providing nutritional counselling
Description: Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: counseling on physical activity
Description: Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling on physical activity
Description: Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)
Study: NCT04803552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight sleep study with Sleepiz One and a respiratory polygraphy
Description: Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~* Thoracic respiratory effort: respiration frequency (BR), respiration curve~* Airflow: respiration frequency (BR), respiration curve~* Body movement: body position~* Blood oxygen saturation (SpO2)~* Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions
Study: NCT06072664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Compensation Index (COMPX)
Description: Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
Study: NCT05510349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonographic measure of placental elasticity and viscosity
Description: Sonographic measure of placental elasticity and viscosity
Study: NCT06255613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring
Description: The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Cor
Description: The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts.
Study: NCT00915616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin